Pedro Guimaraes

Prof. Pedro Guimaraes

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2018 in ACS Nano
Verified
Journal Article
Closed access
PGPedro Guimaraes
Pedro Guimaraes
SGStephanie Gaglione
Stephanie Gaglione
TSTomasz Sewastianik
Tomasz Sewastianik
RCRuben D. Carrasco
Ruben D. Carrasco
RLRobert Langer
Robert Langer
MMMichael Mitchell
Michael Mitchell

1 June 2022 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
SSSérgio Scalzo
Sérgio Scalzo
ASAnderson Kenedy Santos
Anderson Kenedy Santos
HFHeloísa As Ferreira
Heloísa As Ferreira
PCPedro A Costa
Pedro A Costa
PPPedro Hdm Prazeres
Pedro Hdm Prazeres
PGPedro Guimaraes
Pedro Guimaraes
Introduction: Gene therapy is a promising approach to be applied in cardiac regeneration after myocardial infarction and gene correction for inherited cardiomyopathies. However, cardiomyocytes are crucial cell types that are considered hard-to-transfect. The entrapment of nucleic acids in non-viral vectors, such as lipid nanoparticles (LNPs), is an attractive approach for safe and effective delivery. Methods: Here, a mini-library of engineered LNPs was developed for pDNA delivery in cardiomyocytes. LNPs were characterized and screened for pDNA delivery in cardiomyocytes and identified a lead LNP formulation with enhanced transfection efficiency. Results: By varying lipid molar ratios, the LNP formulation was optimized to deliver pDNA in cardiomyocytes with enhanced gene expression in vitro and in vivo, with negligible toxicity. In vitro, our lead LNP was able to reach a gene expression greater than 80%. The in vivo treatment with lead LNPs induced a twofold increase in GFP expression in heart tissue compared to control. In addition, levels of circulating myeloid cells and inflammatory cytokines remained without significant changes in the heart after LNP treatment. It was also demonstrated that cardiac cell function was not affected after LNP treatment. Conclusion: Collectively, our results highlight the potential of LNPs as an efficient delivery vector for pDNA to cardiomyocytes. This study suggests that LNPs hold promise to improve gene therapy for treatment of cardiovascular disease. Graphical Abstract:

18 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LGLays Cordeiro Guimaraes
Lays Cordeiro Guimaraes
PCPedro Augusto Carvalho Costa
Pedro Augusto Carvalho Costa
SJSérgio Ricardo Aluotto Scalzo Júnior
Sérgio Ricardo Aluotto Scalzo Júnior
HFHeloísa Athaydes Seabra Ferreira
Heloísa Athaydes Seabra Ferreira
ABAna Carolina Soares Braga
Ana Carolina Soares Braga
PGPedro Guimaraes
Pedro Guimaraes
A safe and effective vaccine with long-term protection against SARS-CoV-2 variants of concern (VOCs) is a global health priority. Here, we develop lipid nanoparticles (LNPs) to provide safe and effective delivery of plasmid DNA (pDNA) and show protection against VOCs in female small animal models. Using a library of LNPs encapsulating unique barcoded DNA (b-DNA), we screen for b-DNA delivery after intramuscular administration. The top-performing LNPs are further tested for their capacity of pDNA uptake in antigen-presenting cells in vitro. The lead LNP is used to encapsulate pDNA encoding the HexaPro version of SARS-CoV-2 spike (LNP-HPS) and immunogenicity and protection is tested in vivo. LNP-HPS elicit a robust protective effect against SARS-CoV-2 Gamma (P.1), correlating with reduced lethality, decreased viral load in the lungs and reduced lung damage. LNP-HPS induce potent humoral and T cell responses against P.1, and generate high levels of neutralizing antibodies against P.1 and Omicron (B.1.1.529). Our findings indicate that the protective efficacy and immunogenicity elicited by LNP-HPS are comparable to those achieved by the approved COVID-19 vaccine from Biontech/Pfizer in animal models. Together, these findings suggest that LNP-HPS hold great promise as a vaccine candidate against VOCs.

13 June 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PGPedro Guimaraes
Pedro Guimaraes
CFChristian G. Figueroa-Espada
Christian G. Figueroa-Espada
RRRachel S. Riley
Rachel S. Riley
NGNingqiang Gong
Ningqiang Gong
LXLulu Xue
Lulu Xue
MMMichael Mitchell
Michael Mitchell
Multiple myeloma (MM), a hematologic malignancy that preferentially colonizes the bone marrow, remains incurable with a survival rate of 3 to 6 mo for those with advanced disease despite great efforts to develop effective therapies. Thus, there is an urgent clinical need for innovative and more effective MM therapeutics. Insights suggest that endothelial cells within the bone marrow microenvironment play a critical role. Specifically, cyclophilin A (CyPA), a homing factor secreted by bone marrow endothelial cells (BMECs), is critical to MM homing, progression, survival, and chemotherapeutic resistance. Thus, inhibition of CyPA provides a potential strategy to simultaneously inhibit MM progression and sensitize MM to chemotherapeutics, improving therapeutic response. However, inhibiting factors from the bone marrow endothelium remains challenging due to delivery barriers. Here, we utilize both RNA interference (RNAi) and lipid–polymer nanoparticles to engineer a potential MM therapy, which targets CyPA within blood vessels of the bone marrow. We used combinatorial chemistry and high-throughput in vivo screening methods to engineer a nanoparticle platform for small interfering RNA (siRNA) delivery to bone marrow endothelium. We demonstrate that our strategy inhibits CyPA in BMECs, preventing MM cell extravasation in vitro. Finally, we show that siRNA-based silencing of CyPA in a murine xenograft model of MM, either alone or in combination with the Food and Drug Administration (FDA)-approved MM therapeutic bortezomib, reduces tumor burden and extends survival. This nanoparticle platform may provide a broadly enabling technology to deliver nucleic acid therapeutics to other malignancies that home to bone marrow.

1 October 2023 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
PPPedro Henrique Dias Moura Prazeres
Pedro Henrique Dias Moura Prazeres
HFHeloísa Ferreira
Heloísa Ferreira
PCPedro Augusto Carvalho Costa
Pedro Augusto Carvalho Costa
WSWalison da Silva
Walison da Silva
MAMarco Túllio Alves
Marco Túllio Alves
PGPedro Guimaraes
Pedro Guimaraes
Introduction: Chimeric antigen receptor (CAR) cell therapy represents a hallmark in cancer immunotherapy, with significant clinical results in the treatment of hematological tumors. However, current approved methods to engineer T cells to express CAR use viral vectors, which are integrative and have been associated with severe adverse effects due to constitutive expression of CAR. In this context, non-viral vectors such as ionizable lipid nanoparticles (LNPs) arise as an alternative to engineer CAR T cells with transient expression of CAR. Methods: Here, we formulated a mini-library of LNPs to deliver pDNA to T cells by varying the molar ratios of excipient lipids in each formulation. LNPs were characterized and screened in vitro using a T cell line (Jurkat). The optimized formulation was used ex vivo to engineer T cells derived from human peripheral blood mononuclear cells (PBMCs) for the expression of an anti-CD19 CAR (CAR-CD19BBz). The effectiveness of these CAR T cells was assessed in vitro against Raji (CD19+) cells. Results: LNPs formulated with different molar ratios of excipient lipids efficiently delivered pDNA to Jurkat cells with low cytotoxicity compared to conventional transfection methods, such as electroporation and lipofectamine. We show that CAR-CD19BBz expression in T cells was transient after transfection with LNPs. Jurkat cells transfected with our top-performing LNPs underwent activation when exposed to CD19+ target cells. Using our top-performing LNP-9-CAR, we were able to engineer human primary T cells to express CAR-CD19BBz, which elicited significant specific killing of CD19+ target cells in vitro. Conclusion: Collectively, our results show that LNP-mediated delivery of pDNA is a suitable method to engineer human T cells to express CAR, which holds promise for improving the production methods and broader application of this therapy in the future.

1 June 2014 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
DSDiego F. Suárez
Diego F. Suárez
JCJessika Consuegra
Jessika Consuegra
VTVivianne C. Trajano
Vivianne C. Trajano
SGSávio Gontijo
Sávio Gontijo
PGPedro Guimaraes
Pedro Guimaraes
RSRuben Sinisterra
Ruben Sinisterra